


PRODUCT INFORMATION



BETP

Item No. 31116

CAS Registry No.: 1371569-69-5
Formal Name: 2-(ethylsulfinyl)-4-[3-(phenylmethoxy)phenyl]-6-(trifluoromethyl)-pyrimidine
MF: C₂₀H₁₇F₃N₂O₂S
FW: 406.4
Purity: ≥98%
UV/Vis.: λ_{max}: 280 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

BETP is supplied as a crystalline solid. A stock solution may be made by dissolving the BETP in the solvent of choice, which should be purged with an inert gas. BETP is soluble in organic solvents such as DMSO, and dimethyl formamide (DMF). The solubility of BETP in these solvents is approximately 15 and 25 mg/ml, respectively.

BETP is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, BETP should first be dissolved in DMF and then diluted with the aqueous buffer of choice. BETP has a solubility of approximately 0.16 mg/ml in a 1:5 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

BETP is a positive allosteric modulator of glucagon-like peptide 1 receptor (GLP-1R; EC₅₀ = 0.66 μM in a reporter assay).¹ It is selective for GLP-1R over GLP-2R, as well as glucose-dependent insulinotropic polypeptide, glucagon, and the parathyroid hormone receptors. BETP induces cAMP accumulation and intracellular calcium mobilization in CHO cells expressing human GLP-1R (EC₅₀s = 5 and 6.3 μM, respectively).² It increases glucose-induced insulin secretion in pancreatic islets isolated from patients with type 2 diabetes when used at concentrations of 3 and 10 μM. BETP (10 mg/kg) increases plasma insulin levels in an intravenous glucose tolerance test in rats.

References

1. Sloop, K.W., Willard, F.S., Brenner, M.B., *et al.* Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. *Diabetes*. **59(2)**, 3099-3107 (2010).
2. Wootten, D., Savage, E.E., Willard, F.S., *et al.* Differential activation and modulation of the glucagon-like peptide-1 receptor by small molecule ligands. *Mol. Pharmacol.* **83(4)**, 822-834 (2013).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/07/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM